. Author manuscript; available in PMC: 2016 Apr 2.

Published in final edited form as: Breast Cancer Res Treat. 2015 Apr 2;150(3):569–579. doi: 10.1007/s10549-015-3359-6

Table IIIB.

Percent of cells with ≥2 phospho-p65 staining analyzed according to patient and tumor characteristics (Race, ER status, PR status, HER2 status).

		Number	Mean	Std Dev	Median	Minimum	Maximum	LSMean	P-value

Race	White	152	21.78	29.04	7.5	0	100	21.81	0.9931
	Black	154	14.63	23.07	2.08	0	96.67	21.29
	Other	1	10	---	10	10	10	21.37

ER	ER+	138	15.40	25.63	0	0	96.67	24.00	0.4234
ER	ER-	169	20.39	26.82	10	0	100	18.98	0.4234

PR	PR+	128	14.82	25.30	0	0	96.67	20.03	0.6442
PR	PR-	179	20.53	26.92	10	0	100	22.95	0.6442

HER2	HER2+	93	19.73	25.58	10	0	95	26.61	0.0027
HER2	HER2-	214	17.46	26.74	4.17	0	100	16.37	0.0027

Stage	0	1	30	---	30	30	30	12.60	0.0073
	1	77	29.98	32.03	18.33	0	100	25.82
	2	143	14.50	24.06	1.67	0	100	15.35
	3	74	11.19	17.45	3.33	0	90	13.29
	4	5	44	37.59	53.33	0	93.33	40.40